From growth companies to multinationals and leading institutions, we offer a wealth of expertise in corporate transactions to a diverse and innovative client base. Our advice is clear, pragmatic and, crucially, aligned with the client’s strategic goals.

Our experienced lawyers advise on every aspect of corporate transactions and leverage the firm’s full-service offering to provide business-critical advice in key areas such as tax, employment, UK and EU competition/anti-trust, regulatory, real estate, IT, data protection and IP issues.

Our market-leading strengths in IP and technology mean we are uniquely well-placed to counsel clients in dynamic sectors such as technology, life sciences and brands. We draw on our understanding of these sectors to advise corporate and institutional clients acquiring or evaluating IP and technology portfolios, helping them to secure commercially-relevant legal protections and to acquire, sell or invest with confidence.

We carry out both domestic and cross-border transactional work advising on private and public mergers & acquisitions, disposals, spin-outs, and corporate reorganisations. We also have considerable experience of advising on domestic and international joint ventures, helping our clients expand and develop their business into new areas and new markets.

With regard to finance transactions, we act for businesses raising finance as well as for the finance providers including venture capital firms, private equity firms and corporate venturing houses. We are recognised for our market leading expertise advising technology and life sciences growth companies at all stages of the evolutionary cycle of equity financing transactions including early stage financings, Series A and Series B, growth equity and pre-IPO cross-over finance. We also advise numerous equity providers in these sectors on their investments from Series A onwards and act for many of the world’s leading companies on their corporate venturing programmes.

Our debt experience includes advising on corporate borrowing and secured lending transactions, acquisition finance and debt refinance as well as venture debt and convertible equity instruments.

We also offer the full range of services for equity capital market (ECM) transactions and have experience in handling primary and secondary offerings on both the UK markets and NASDAQ from a UK perspective.

On cross-border transactions, we draw on a network of specialist lawyers from independent law firms around the world in order to provide a seamless service. A key differentiator of Bristows’ network as compared with that of “global brand” firms is our ability to choose the best firms for any particular transaction rather than being tied to one firm or office in each jurisdiction.

Key contact

Iain Redford



We advised epigenetics company Base Genomics on its $11 million USD seed financing to commercialise their technology for early and sensitive detection of cancer from liquid biopsy.

DeepMatter Group plc on the sale of the lonscope business, its acquisition of InfoChem from Springer Nature, placing and Rule 9 Takeover Code waiver.

Hedge fund Tybourne Capital Management on its Series B investments into Bicycle Therapeutics limited, a clinical stage biotechnology company.

IP Group plc on the transfer back to Imperial College of the technology transfer office of the university.

Janssen on its participation in the establishment of the UK's first dedicated Vaccines Manufacturing Innovation Centre, as part of a consortium of academic and industry partners.

Syncona as lead investor in the Series A financing of OMass Therapeutics, a spin-out from Oxford University.

Capgemini on the acquisition of Adaptive Labs.

OneTrust, the global leader in privacy management and marketing compliance software, on its acquisitions of Governor Technology and DataGuidance.

Accel-KKR on its growth equity investment in global managed payroll and GEO SaaS business Safeguard Global.

Boeing HorizonX Ventures, the corporate venturing arm of Boeing, on its UK investments - including its investment into Reaction Engines.

AI-powered search marketing intelligence company Adthena on its Series A funding from Updata Partners.

Latest articles

What others say

“Bristows was a valued partner in the success of making our vision become a reality.”

Stephanie Morris, Director of Industry Partnerships and Commercialisation at Imperial College London

“They enabled a very positive conclusion to the overall deal.”

Richard Fagan, Director of BioPharma at UCL Business

“Their expertise made them the perfect partner to work with on the highly complex Apollo transaction.”

Richard Fagan, Director of BioPharma at UCL Business

“UCLB has worked with Bristows for over 25 years, in relation to intellectual property licensing transactions as well as corporate transactions such as spinout formation.”

Richard Fagan, Director of BioPharma at UCL Business

“Bristows’ knowledge of the life sciences market and players, as well as their licensing expertise, was invaluable as we navigated this complex transaction.”

Iain Thomas, Cambridge Enterprise’s Head of Life Sciences

“Excellent advice on UK and European commercial and corporate transactions for emerging innovators as well as giants of the life sciences industry.”

Chambers and Partners Global 2021

“They bring a strong risk management perspective to the advice that they provide.”

Legal 500 2021

“In a regulatory and commercial environment fraught with uncertainty, the Bristows team help their clients navigate through issues in a practical way with a clear road map towards a solution which is in line with the client objective.”

Legal 500 2021

“Good team with specialist life science expertise, brings commercial/IP and corporate side together well on transactions.”

Legal 500 2021

“They always had an open ear for my needs, were open for discussions and brainstormings and are very easy to work with.”

Legal 500 2021

“Bristows has a ‘first-rate life sciences team’.”

Legal 500 2021

“Excellent people, thoughtful advice, easy to contact.”

Legal 500 2021

“Whether it’s an immediate need to a crisis or longer term strategic support the team are always there.”

Legal 500 2021

“Great team, always willing to help and support.”

Legal 500 2021

Bristows offers excellent advice with a broad range of skills”

Legal 500 2020

Recent rankings and awards

M&A: (smaller deals up to £50m) - Tier 1
Legal 500 2021

Fintech - Tier 3
Legal 500 UK 2021

Life Sciences: Transactional - Band 2
Chambers and Partners UK 2021